McAnena Lisa, Doyle Frank, O'Keefe Michael
Eye Department, Temple Street Children's University Hospital, Dublin, Ireland.
Royal College of Surgeons in Ireland (RCSI), Dublin, Ireland.
Acta Ophthalmol. 2017 May;95(3):229-239. doi: 10.1111/aos.13224. Epub 2016 Sep 28.
Keratoconus can behave more aggressively in pediatric than in adult patients. We systematically reviewed the literature to determine the effectiveness of corneal collagen cross-linking (CXL) in children. For this study, MEDLINE and Cochrane databases were searched for all studies examining the effects of standard, trans-epithelial or accelerated CXL protocols in patients age 18 years or younger. Primary outcomes were; uncorrected visual acuity (UCVA) and maximum keratometry (Kmax) and secondary outcomes were; best-corrected visual acuity (BCVA), mean refractive spherical equivalent (MRSE), central corneal thickness (CCT) and endothelial cell density (ECD). Standardized mean differences (SMD) and 95% confidence intervals were calculated, comparing baseline values with those at 6, 12 and 24 months. A total of 13 papers, published between May 2011 and December 2014 examining 490 eyes of 401 patients with a mean age of 15.25 (±1.5) years, were included in the qualitative analysis in this review. Nine papers were included in the meta-analysis, showing significant improvement in UCVA and BCVA and stable Kmax at 12 months, and stable UCVA, improved BCVA and improved Kmax at 24 months in the standard protocol group UCVA, BCVA and KMax were stable at 12 months in the trans-epithelial group. Mean refractive spherical equivalent (MRSE), CCT and ECD remained stable in both groups. In conclusion it was found that standard CXL may be effective in halting progression of keratoconus in pediatric patients at 1 year. However, larger, more long-term studies are required to ascertain its effectiveness.
圆锥角膜在儿童患者中比在成人患者中进展更为迅猛。我们系统回顾了文献,以确定角膜胶原交联(CXL)在儿童中的有效性。在本研究中,检索了MEDLINE和Cochrane数据库,以查找所有研究18岁及以下患者标准、经上皮或加速CXL方案效果的研究。主要结局指标为:未矫正视力(UCVA)和最大角膜曲率(Kmax),次要结局指标为:最佳矫正视力(BCVA)、平均等效球镜度(MRSE)、中央角膜厚度(CCT)和内皮细胞密度(ECD)。计算标准化均数差(SMD)和95%置信区间,将基线值与6、12和24个月时的值进行比较。共有13篇发表于2011年5月至2014年12月的论文纳入本综述的定性分析,研究了401例患者的490只眼,平均年龄为15.25(±1.5)岁。9篇论文纳入荟萃分析,结果显示标准方案组在12个月时UCVA和BCVA显著改善,Kmax稳定,在24个月时UCVA稳定、BCVA改善且Kmax改善;经上皮组在12个月时UCVA、BCVA和KMax稳定。两组的平均等效球镜度(MRSE)、CCT和ECD均保持稳定。总之,发现标准CXL可能在1年内有效阻止儿童圆锥角膜的进展。然而,需要更大规模、更长期的研究来确定其有效性。